Silexion Therapeutics Corp. (SLXN)
0.3676
-0.03
(-6.72%)
USD |
NASDAQ |
Aug 24, 16:00
0.3602
-0.01
(-2.01%)
After-Hours: 20:00
Silexion Therapeutics Enterprise Value : -0.4143M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | -0.4143M |
| August 21, 2026 | -0.383M |
| August 20, 2026 | -0.3773M |
| August 19, 2026 | -0.3605M |
| August 18, 2026 | -0.3546M |
| August 17, 2026 | -0.3501M |
| August 14, 2026 | -0.3522M |
| August 13, 2026 | -0.3053M |
| August 12, 2026 | -0.3123M |
| August 11, 2026 | 0.3731M |
| August 10, 2026 | 0.9217M |
| August 07, 2026 | 1.358M |
| August 06, 2026 | 1.264M |
| August 05, 2026 | 1.276M |
| August 04, 2026 | 1.394M |
| August 03, 2026 | 1.453M |
| July 31, 2026 | 1.37M |
| July 30, 2026 | 1.323M |
| July 29, 2026 | 1.040M |
| July 28, 2026 | 2.042M |
| July 27, 2026 | 2.137M |
| July 24, 2026 | 1.830M |
| July 23, 2026 | 1.960M |
| July 22, 2026 | 2.125M |
| July 21, 2026 | 2.113M |
| Date | Value |
|---|---|
| July 20, 2026 | 2.208M |
| July 17, 2026 | 2.196M |
| July 16, 2026 | 2.432M |
| July 15, 2026 | 2.196M |
| July 14, 2026 | 2.102M |
| July 13, 2026 | 2.102M |
| July 10, 2026 | 2.208M |
| July 09, 2026 | 2.231M |
| July 08, 2026 | 2.267M |
| July 07, 2026 | 2.385M |
| July 06, 2026 | 2.514M |
| July 02, 2026 | 2.273M |
| July 01, 2026 | 2.202M |
| June 30, 2026 | 2.160M |
| June 29, 2026 | 0.3526M |
| June 26, 2026 | 0.4089M |
| June 25, 2026 | 0.4027M |
| June 24, 2026 | 0.3933M |
| June 23, 2026 | 0.3964M |
| June 22, 2026 | 0.3933M |
| June 18, 2026 | 0.4027M |
| June 17, 2026 | 0.4558M |
| June 16, 2026 | 0.3964M |
| June 15, 2026 | 0.4089M |
| June 12, 2026 | 0.5278M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioLineRx Ltd. | 8.933M |
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 428.03M |
| Can-Fite BioPharma Ltd. | -4.492M |
| Galmed Pharmaceuticals Ltd. | -12.23M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.551M |
| Total Expenses (Quarterly) | 3.551M |
| EPS Diluted (Quarterly) | -5.166 |
| Earnings Yield | -15.38K% |
| Normalized Earnings Yield | -15459.25 |